3 results
Approved WMOCompleted
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMORecruiting
Objective 1: analyze the effect of short-term treatment with high dose glucocorticoids on vasculopathic abnormalities as measured by NCM in patients with very early SSc.Objective 2: investigate the effects of glucocorticoids on signs and symptoms of…